Okay, deep breath, let's get this over with. In the grand act of digital self-sabotage, we've littered this site with cookies. Yep, we did that. Why? So your highness can have a 'premium' experience or whatever. These traitorous cookies hide in your browser, eagerly waiting to welcome you back like a guilty dog that's just chewed your favorite shoe. And, if that's not enough, they also tattle on which parts of our sad little corner of the web you obsess over. Feels dirty, doesn't it?
Pharma Data Breach Fiasco: Cencora’s $250B Security Slip-Up Exposes Millions
Big pharma’s data theft saga continues as Cencora’s February breach spills over, affecting health details from GlaxoSmithKline to Novartis. The $250-billion firm, formerly AmerisourceBergen, faces scrutiny as pharma giants report losses to California’s AG. How many individuals are impacted remains unclear.
Hot Take:
Who knew pharmaceutical data breaches could be the next big pill to swallow? Cencora’s breach has more side effects than a bad infomercial, and now the whole pharma industry is scrambling to find the right prescription for their data security woes!
Key Points:
- More than a dozen pharmaceutical suppliers reported data theft due to Cencora’s February breach.
- Notified individuals’ data includes names, addresses, birth dates, health diagnoses, and medication details.
- No current evidence suggests the stolen data has been used fraudulently.
- Cencora’s breach did not impact company operations materially, but future financial impacts are uncertain.
- California Attorney General was informed, but the total number of affected individuals remains unclear.
Already a member? Log in here